Rosario García‐Campelo

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009 · 2.4K citations · Full text

Medicine, Genetics, Oncology +11

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Rafael Rosell, Miguel Angel Molina, Carlota Costa et al. · Clinical Cancer Research · 2011 · 300 citations · Full text

Medicine, Molecular Biology, Oncology +17

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj et al. · Clinical Cancer Research · 2014 · 228 citations · Full text

Medicine, Oncology, Pharmacology +15

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

Margarita Majem, Óscar Juan, Amelia Insa et al. · Clinical & Translational Oncology · 2018 · 183 citations · Full text

Medicine, Molecular Medicine, Oncology +17